Phaseline

Targets › APOC3

APOC3 (Apolipoprotein C-III): drug programs, companies and trials

4 programs from 4 companies in 12 trials: 8 Phase 3, 4 Phase 2; Metabolic and endocrine, Gastroenterology; next expected readout Jan 2027.

Component of triglyceride-rich very low density lipoproteins (VLDL) and high density lipoproteins (HDL) in plasma. Plays a multifaceted role in triglyceride homeostasis. (UniProt, P02656)

Open in Phaseline: the race on APOC3, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Ionis PharmaceuticalsOlezarsen
Apolipoprotein C-III mRNA antisense inhibitor
APOC3Phase 3Severe Hypertriglyceridemia; Familial Chylomicronemia SyndromeMar 2027
Arrowhead PharmaceuticalsPlozasiran
APOC3 antisense oligonucleotide
APOC3Phase 3Severe Hypertriglyceridemia; HypertriglyceridemiaJul 2028
Fujian Shengdi PharmaceuticalHRS-7249 Injection
GalNAc-conjugated APOC3-targeted siRNA
APOC3Phase 2Hyperlipidemia; Severe Hypertriglyceridemia With a High Risk of Acute PancreatitisJan 2027
Eli LillySolbinsiran (LY3561774)
Antisense oligonucleotide targeting APOC3 mRNA, reducing apoC-III levels and triglycerides
APOC3Phase 2Severe HypertriglyceridemiaMar 2027

Conditions

Severe Hypertriglyceridemia (5) Familial Chylomicronemia Syndrome (3) Hyperlipidemia (2) Hypertriglyceridemia (1) Severe Hypertriglyceridemia With a High Risk of Acute Pancreatitis (1)

Modalities

other (3), small molecule (1)

Companies

Eli Lilly (1) Ionis Pharmaceuticals (1) Arrowhead Pharmaceuticals (1) Fujian Shengdi Pharmaceutical (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.